For patients with acute lymphoblastic leukemia (ALL), allogeneic hematopoietic cell transplantation (alloHCT) offers a potential cure. Life-threatening complications can arise from alloHCT that require the application of sophisticated health care delivery. The impact of country-level economic conditions on post-transplantation outcomes is not known. Our objective was to assess whether these variables were associated with outcomes for patients transplanted for ALL. Using data from the Center for Blood and Marrow Transplant Research, we included 11,261 patients who received a first alloHCT for ALL from 303 centers across 38 countries between the years of 2005 and 2013. Cox regression models were constructed using the following macroeconomic indicators as main effects: Gross national income per capita, health expenditure per capita, and Human Development Index (HDI). The outcome was overall survival at 100 days following transplantation. In each model, transplants performed within lower resourced environments were associated with inferior overall survival. In the model with the HDI as the main effect, transplants performed in the lowest HDI quartile (n = 697) were associated with increased hazard for mortality (hazard ratio, 2.42; 95% confidence interval, 1.64 to 3.57; P <.001) in comparison with transplants performed in the countries with the highest HDI quartile. This translated into an 11% survival difference at 100 days (77% for lowest HDI quartile versus 88% for all other quartiles). Country-level macroeconomic indices were associated with lower survival at 100 days after alloHCT for ALL. The reasons for this disparity require further investigation.
Bibliographical noteFunding Information:
Funding: The CIBMTR is supported by Public Health Service Grant / Cooperative Agreement 5U24-CA076518 from the NCI , NHLBI , and NIAID .
Funding: The CIBMTR is supported by Public Health Service Grant / Cooperative Agreement 5U24-CA076518 from the NCI, NHLBI, and NIAID.
© 2018 The American Society for Blood and Marrow Transplantation
- Bone marrow
- Health expenditures
- Hematopoietic stem cell transplantation
- Outcome assessment (Health care)
- Precursor cell lymphoblastic leukemia-lymphoma